Emergent BioSolutions (NYSE:EBS) Shares Up 4.9%

Shares of Emergent BioSolutions Inc. (NYSE:EBS) shot up 4.9% during trading on Tuesday . The stock traded as high as $12.23 and last traded at $12.02. 426,182 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 3,851,275 shares. The stock had previously closed at $11.46.

Analyst Upgrades and Downgrades

Separately, Benchmark reaffirmed a “buy” rating and issued a $8.00 price target on shares of Emergent BioSolutions in a research note on Tuesday, July 2nd.

Emergent BioSolutions Stock Up 9.0 %

The company has a current ratio of 1.08, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. The company has a market cap of $654.48 million, a PE ratio of -1.09 and a beta of 1.62. The company’s 50 day moving average is $7.07 and its 200 day moving average is $4.03.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of ($3.65) by $4.24. Emergent BioSolutions had a negative net margin of 47.68% and a negative return on equity of 18.53%. The business had revenue of $300.40 million during the quarter. During the same quarter in the prior year, the firm posted ($3.17) EPS. As a group, analysts predict that Emergent BioSolutions Inc. will post -1.98 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Kathryn C. Zoon sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $6.11, for a total transaction of $61,100.00. Following the completion of the transaction, the director now owns 54,482 shares in the company, valued at approximately $332,885.02. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 12,919 shares of company stock worth $75,831. 1.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. SG Americas Securities LLC increased its stake in Emergent BioSolutions by 171.7% during the 4th quarter. SG Americas Securities LLC now owns 66,011 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 41,712 shares in the last quarter. CoreCap Advisors LLC acquired a new position in Emergent BioSolutions during the 4th quarter valued at approximately $33,000. Assenagon Asset Management S.A. increased its stake in Emergent BioSolutions by 356.2% during the 4th quarter. Assenagon Asset Management S.A. now owns 834,372 shares of the biopharmaceutical company’s stock valued at $2,002,000 after purchasing an additional 651,480 shares in the last quarter. Values First Advisors Inc. increased its stake in Emergent BioSolutions by 101.6% during the 4th quarter. Values First Advisors Inc. now owns 307,892 shares of the biopharmaceutical company’s stock valued at $739,000 after purchasing an additional 155,193 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in Emergent BioSolutions by 1.5% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 460,289 shares of the biopharmaceutical company’s stock valued at $1,105,000 after purchasing an additional 6,724 shares in the last quarter. Institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.